BioNxt Solutions Prepares for Human Bioequivalence Study For MS
23.4.2025 03:05:00 CEST | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment.
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish.
The Company plans to make further updates in the coming weeks regarding its bioequivalent study preparation and scheduling, as well integration of its research and development operations with Gen-Plus.
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
The Market Has Spoken: BridgeLink Surpasses 10,000 Downloads, Solidifying Status as the Global Standard for Open-Source Health Interoperability27.1.2026 18:35:00 CET | Press release
MONTGOMERY, AL / ACCESS Newswire / January 27, 2026 / Innovar Healthcare today announced that BridgeLink, the open-source integration engine, has surpassed 10,000 enterprise downloads, a milestone that signals a decisive shift in the healthcare IT landscape. Following the market shift toward restrictive proprietary licensing for the industry's legacy engine, the healthcare community has decisively moved to BridgeLink as the premier open-source replacement. This rapid adoption-achieved in less than a year since its March 2025 launch-confirms that healthcare organizations are prioritizing strategic resilience and technical transparency over vendor lock-in. BridgeLink is no longer just an alternative; it has become the operational standard for hospitals, Digital Health, Health Information Exchanges (HIEs), and laboratories worldwide seeking to secure their interoperability infrastructure. "The volume of downloads we are seeing represents a 'Great Migration' in health tech," said Loyd Bitt
Symetrix Unveils Cognio: The Next-Generation Audio, Video, and Control Platform27.1.2026 14:15:00 CET | Press release
With breakthrough distributed architecture and wire-free design workflows, Cognio redefines how AV systems are designed, deployed, and operated; see it for the first time at ISE 2026 SEATTLE, WA / ACCESS Newswire / January 27, 2026 / Symetrix, a global leader in high-performance AV processing, control, and monitoring solutions, today announced the launch of Cognio™, a brand-new software-driven Audio, Video, and Control (AVC) ecosystem designed to dramatically simplify system design, accelerate deployment, and deliver more flexible, scalable AV experiences. Cognio will make its official public debut at Integrated Systems Europe (ISE) 2026 in Barcelona, where attendees can experience an entirely new approach to deploying Audio, Video, and Control solutions at the Symetrix booth (5M390). Cognio represents a fundamental rethinking of how AV systems are built, combining distributed intelligence with code-free control into a single platform powered by DesignOps, the patented software that un
U.S. Polo Assn. Celebrates a Landmark Debut as the Official Jersey and Apparel Partner of the 41st Snow Polo World Cup St. Moritz27.1.2026 13:00:00 CET | Press release
Standing Rock Claims Victory Over Flexjet in a Thrilling Final Showdown WEST PALM BEACH, FL AND ST. MORITZ, SWITZERLAND / ACCESS Newswire / January 27, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), celebrated its inaugural year as the Official Jersey and Apparel Partner of the 41st Snow Polo World Cup St. Moritz. The legendary three-day competition and record-breaking lifestyle event took place on the iconic frozen Lake St. Moritz in Switzerland's Engadin Valley and featured world-class competition, alpine elegance, fan activations, VIP experiences, and global sport celebration. More than 2,400 tons of infrastructure were installed directly onto the frozen lake of St. Moritz for this one-of-a-kind event. After two days and eight games of preliminaries, on Sunday, Jan. 25, Standing Rock prevailed over Flexjet in a close 6 - 4.5 victory.1. The intensity was high in the final Snow Polo World Cup game, with Standing Rock ultimately prevaili
AM Positions for Next Phase of Global Growth: Kelly McAndrew to Chairman; Dave Watrous to CEO27.1.2026 07:00:00 CET | Press release
AUSTIN, TX / ACCESS Newswire / January 27, 2026 / For over 21 years, Kelly McAndrew has served as Chief Executive Officer (CEO), playing a pivotal role in shaping AM Technical Solutions (AM) culture and strategic direction, enabling exceptional results. Kelly now transitions into the role of Chairman of the Board. As Chairman, Kelly will focus on investments and partnerships to further enhance the company's solution offerings. Dave Watrous will succeed Kelly as Chief Executive Officer. AM has worked closely with Dave for more than six years in the roles of customer and partner. His faith, integrity, leadership qualities, and strong industry expertise make him the ideal choice for this role. With a distinguished 30-year career in High-Technology industries, Dave brings extensive capabilities in delivering multi-billion-dollar Engineering, Procurement, Construction, Commissioning, and Validation projects worldwide. As CEO, Dave will focus on leading growth, accelerating opportunities, en
Richter Extends Its Support to Africa - The First Year of the House of Hope in Bamako in Numbers26.1.2026 14:00:00 CET | Press release
The First Year of the House of Hope in Bamako in Numbers BUDAPEST, HU / ACCESS Newswire / January 26, 2026 / Nearly one year has passed since the House of Hope centre, established by Richter Gedeon Plc., began providing shelter and comprehensive support to women in Bamako. During this period, almost 120 women and girls have benefited from healthcare, legal aid and education. Interest in the centre remains strong, with new women continuously joining the programme. In the coming years, the initiative aims to reach several hundred vulnerable women across different regions of Mali. Why Was the House of Hope Established? The centre was created through the collaboration of Richter Gedeon Plc. (Richter), the Hungary-based Close to Africa Foundation, and the local Sini Sanuman Foundation. Its mission is to provide safety and professional support to women fleeing violence and abuse through gynaecological care, psychological and legal counselling, and educational programmes. The building was des
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom